It decreased TNF-α, a key factor in Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH) development, as well as IL-6, IL-10, and IL-17A, which are implicated in obesity and NAFLD regulation. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.